Expansion of a US generic drug price-fixing lawsuit brought by 46 states and territories seems likely to continue even after the addition of 12 companies and two executives as defendants.
"Our ongoing investigation continues to uncover additional evidence, and we anticipate bringing more claims involving additional companies and drugs at the appropriate time," Connecticut Attorney General George Jepson said in an Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?